Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer, specifically for adult patients with previously treated advanced, unresectable, or metastatic melanoma. It also markets Proleukin, an interleukin-2 product for metastatic melanoma and metastatic renal cell carcinoma. Additionally, Iovance has a robust pipeline including lifileucel for melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC), as well as other candidates like LN-145-S1, LN-145 Gen 3, IOV-2001, IOV-4001, and IOV-3001.

Iovance Biotherapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol IOVA. The trading currency is the US Dollar (USD), as the company is based in the United States. Being listed on Nasdaq provides the company with access to a broad base of investors and liquidity in the US equity markets.

Iovance Biotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative cell therapies for cancer treatment, leveraging its expertise in tumor infiltrating lymphocytes (TILs) to address solid tumor cancers. The company's work involves complex biological research and clinical development, typical of the biotech industry, with a commercial-stage product already on the market.

Iovance Biotherapeutics is headquartered in San Carlos, California, United States. The company serves markets in the United States and globally, as indicated by its description summary. It has collaborations and licensing agreements with entities such as the National Institutes of Health, the National Cancer Institute, Cellectis S.A., Novartis Pharma AG, and Boehringer Ingelheim Biopharmaceuticals GmbH, reflecting its international reach and partnerships in drug development.

Iovance Biotherapeutics generates revenue through the commercialization of its approved cell therapies, primarily Amtagvi and Proleukin. Amtagvi is an individualized T cell therapy for solid tumor cancers, specifically for advanced melanoma, while Proleukin is an interleukin-2 product used for metastatic melanoma and renal cell carcinoma. The company also has a pipeline of investigational therapies, including lifileucel for multiple cancer types, LN-145-S1, LN-145 Gen 3, IOV-2001 for chronic lymphocytic leukemia and small lymphocytic lymphoma, IOV-4001 for melanoma and NSCLC, and IOV-3001 for TIL therapy. These products are developed through internal research and collaborations with organizations like the National Cancer Institute and Novartis.